Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953265 | 0.86 | KDM4E (0.55) | NPC1CXCR3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL5974075 | 0.86 | POLB (0.47) | NPC1KDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL16792473 | 0.85 | NPC1 (0.42) | NPC1CXCR3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL22113991 | 0.85 | ALDH1A1 (0.43) | NPC1CXCR3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL7911241 | 0.82 | NPC1 (0.40) | NPC1CXCR3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL16792476 | 0.82 | KDM4E (0.51) | NPC1KDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL8272037 | 0.82 | NPC1 (0.40) | NPC1CXCR3KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL14417641 | 0.81 | BRD4 (0.41) | NPC1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL6259455 | 0.78 | NPC1 (0.42) | NPC1KDM4EHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL29520372 | 0.78 | NPC1 (0.42) | NPC1KDM4EHSD17B10ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11286243-B2 | Ferroportin inhibitors and methods of use | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3894416-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | Global Blood Therapeutics, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286243-B2 | Ferroportin inhibitors and methods of use | SLC40A1, HAMP, SFXN1 | NPC1 360/4885CXCR3 950/4885KDM4E 4527/4885 |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | SLC40A1, HAMP, TFRC | NPC1 163/4885CXCR3 3098/4885KDM4E 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.